Thanks luu for posting this paper. I have a quick question about "the specific DNA [sites]" in carbapenem-resistant bacteria that "RNA-guided nucleases (RGNs) t

Thanks luu for posting this paper. I have a quick question about "the specific DNA [sites]" in carbapenem-resistant bacteria that "RNA-guided nucleases (RGNs) targets". Would then this involve regular iterations of new designs of this "RNA-guided" anti-biotics, as newer strands of carbapenem-resistant bacteria evolves and there are new DNA site variations that the anti-biotic needs to target? (Otherwise, if the design is not constantly updated, would it only create evolutionary pressure to select out the current dominant strand of carpaenem-resistance in favor of potential newer mutations?)